Heart 2000;83:278-282 ( March )

Cardiovascular medicine

Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP S Talwar^a, A Siebenhofer^b, B Williams^b, L Ng^a

^a Department of Medicine and Therapeutics, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK, ^b Cardiovascular Research Institute, University of Leicester, Leicester, UK

Correspondence to: Dr Ng email: LLN1{at}le.ac.uk

Accepted 25 October 1999

OBJECTIVESTo examine the relation between plasma concentration of the N terminal of the precursor of brain natriuretic peptide (NT proBNP), left ventricular hypertrophy (LVH), and left ventricular systolic dysfunction (LVSD) in patients with a history of hypertension.
DESIGNProspective study.
SETTINGTeaching hospital based study.
PATIENTSNT proBNP concentrations were determined in five groups of individuals. Group 1: 15 echocardiographic normal controls; group 2: 22 patients with hypertension, normal left ventricular systolic function, and no LVH; group 3: 24 patients with hypertension, normal left ventricular systolic function, and LVH; group 4: 13 patients with history of hypertension, no history of ischaemic heart disease, and left ventricular wall motion index (WMI) between 1.9-1.3; and group 5:17 patients with a history of hypertension, no history of ischaemic heart disease, and WMI < 1.2.
RESULTS Median (range) NT proBNP concentrations (in fmol/ml) for groups 1-5, respectively, were: 129.4 (53.6-159.7), 147.4 (54.3-730.5), 137.1 (35.8-403.9), 356.7 (124.4-934.4), and 493.5 (248.9-909). Mean log NT proBNP differed among all five groups (p < 0.0001), and between groups 4 and 5 versus groups 1-3 (p < 0.0001), and group 4 versus group 5 (p = 0.02) only.
CONCLUSIONSThe results suggest that the presence of hypertension with or without LVH (and normal left ventricular systolic function) does not affect NT proBNP concentrations. Moreover, there is a significant rise in NT proBNP only when LVSD develops in hypertension. Thus, NT proBNP remains a useful diagnostic aid for LVSD, even in hypertensive patients.


Keywords: hypertension; brain natriuretic peptide; left ventricular hypertrophy; left ventricular systolic dysfunction; chemiluminescence

---

© 2000 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Olsson, L. G., Swedberg, K., Cleland, J. G.F., Spark, P. A., Komajda, M., Metra, M., Torp-Pedersen, C., Remme, W. J., Scherhag, A., Poole-Wilson, P., COMET investigators, (2007). Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a {beta}-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 9: 795-801 [Abstract] [Full Text]  
• Belluardo, P., Cataliotti, A., Bonaiuto, L., Giuffre, E., Maugeri, E., Noto, P., Orlando, G., Raspa, G., Piazza, B., Babuin, L., Chen, H. H., Martin, F. L., McKie, P. M., Heublein, D. M., Burnett, J. C. Jr., Malatino, L. S. (2006). Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 291: H1529-H1535 [Abstract] [Full Text]  
• Mueller, T., Gegenhuber, A., Dieplinger, B., Poelz, W., Haltmayer, M. (2005). Capability of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP as Indicators of Cardiac Structural Disease in Asymptomatic Patients with Systemic Arterial Hypertension. Clin. Chem. 51: 2245-2251 [Abstract] [Full Text]  
• Gluud, C., Gluud, L. L. (2005). Evidence based diagnostics. BMJ 330: 724-726 [Full Text]  
• Heidenreich, P. A., Gubens, M. A., Fonarow, G. C., Konstam, M. A., Stevenson, L. W., Shekelle, P. G. (2004). Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43: 1019-1026 [Abstract] [Full Text]  
• Dahlstrom, U. (2004). Can natriuretic peptides be used for the diagnosis of diastolic heart failure?. Eur J Heart Fail 6: 281-287 [Abstract] [Full Text]  
• Alehagen, U., Lindstedt, G., Eriksson, H., Dahlstrom, U. (2003). Utility of the Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma for the Evaluation of Cardiac Dysfunction in Elderly Patients in Primary Health Care. Clin. Chem. 49: 1337-1346 [Abstract] [Full Text]  
• Ruskoaho, H. (2003). Cardiac Hormones as Diagnostic Tools in Heart Failure. Endocr. Rev. 24: 341-356 [Abstract] [Full Text]  
• Mir, T. S., Marohn, S., Laer, S., Eiselt, M., Grollmus, O., Weil, J. (2002). Plasma Concentrations of N-Terminal Pro-Brain Natriuretic Peptide in Control Children From the Neonatal to Adolescent Period and in Children With Congestive Heart Failure. Pediatrics 110: e76-76 [Abstract] [Full Text]  
• Dixon, I. M.C. (2002). A new altruist on the block: effects of adrenomedullin after myocardial infarction. Cardiovasc Res 56: 347-349 [Full Text]  
• Sackett, D L, Haynes, R B (2002). Evidence base of clinical diagnosis: The architecture of diagnostic research. BMJ 324: 539-541 [Full Text]  
• Boomsma, F., van den Meiracker, A. H. (2001). Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 51: 442-449 [Full Text]